Biocartis Group 将来の成長

Future 基準チェック /26

Biocartis Groupは収益が増加すると予測されています。

主要情報

n/a

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長	22.5%
収益成長率	22.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	10 Aug 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

LSE:0R72 - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	100	N/A	N/A	N/A	1
12/31/2024	76	N/A	N/A	N/A	1
12/31/2023	58	N/A	N/A	N/A	1
6/30/2023	61	-68	-51	-50	N/A
3/31/2023	59	-67	-49	-47	N/A
12/31/2022	58	-65	-47	-45	N/A
9/30/2022	58	-64	-53	-50	N/A
6/30/2022	59	-63	-60	-56	N/A
3/31/2022	57	-67	-64	-61	N/A
12/31/2021	55	-71	-69	-66	N/A
9/30/2021	58	-70	-60	-57	N/A
6/30/2021	61	-69	-51	-48	N/A
3/31/2021	58	-66	-47	-44	N/A
12/31/2020	56	-63	-42	-39	N/A
9/30/2020	47	-64	-47	-45	N/A
6/30/2020	38	-66	-51	-50	N/A
3/31/2020	38	-65	-54	-52	N/A
12/31/2019	38	-64	-57	-54	N/A
9/30/2019	35	-60	-56	-52	N/A
6/30/2019	33	-56	-56	-50	N/A
3/31/2019	31	-52	-52	-46	N/A
12/31/2018	29	-48	-48	-42	N/A
9/30/2018	29	-44	-46	-41	N/A
6/30/2018	29	-40	-45	-40	N/A
3/31/2018	26	-41	-45	-40	N/A
12/31/2017	23	-42	-46	-41	N/A
9/30/2017	19	-46	-51	-46	N/A
6/30/2017	14	-50	-56	-50	N/A
3/31/2017	14	-50	N/A	-52	N/A
12/31/2016	14	-50	N/A	-53	N/A
9/30/2016	14	-48	N/A	-49	N/A
6/30/2016	14	-47	N/A	-44	N/A
3/31/2016	15	-43	N/A	-36	N/A
12/31/2015	15	-40	N/A	-27	N/A
9/30/2015	15	-35	N/A	-28	N/A
6/30/2015	15	-30	N/A	-28	N/A
3/31/2015	13	-29	N/A	-32	N/A
12/31/2014	10	-29	N/A	-36	N/A
12/31/2013	12	-27	N/A	-41	N/A
12/31/2012	6	-37	N/A	-41	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0R72の予測収益成長が貯蓄率 ( 1.5% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 0R72の収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 0R72の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 0R72の収益 ( 22.3% ) UK市場 ( 3.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0R72の収益 ( 22.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0R72の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Biocartis Group 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Reconfirms Production Guidance of 2021

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

New minor risk - Share price stability

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings released: €1.24 loss per share (vs €1.11 loss in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.38

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

Revenue beats expectations

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

New 90-day low: €4.15

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

New 90-day high - €5.03

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘